Home › Forums › Clinical Practice › prescribing GLP-1s in psychiatry › Reply To: prescribing GLP-1s in psychiatry

#1334
Jessica Friedman

    I echo some of the same concerns that have already been posted. Some additional thoughts:1) I assume that some of the rationale for prescribing GLP1-RAs to patients in a psychiatry residency is around the metabolic adverse effects of atypical antipsychotics. I imagine that it’s quite challenging to have these medications that can be so effective from a psychiatric perspective and yet carry significant metabolic and weight-related side effects. I can understand wanting to have a tool to be able to offer patients to mitigate those side effects. That being said:

    – I am not aware of any studies that have looked at patient-centered outcomes of GLP1-RAs and antipsychotics. I think it’s reasonable to expect the same short-term benefits regarding weight, diabetes incidence, etc. but also to note that the evidence base isn’t there and that this is an off-label indication. I recognize that so much in psychiatry is off-label, and this is also a teachable opportunity.

    – Are these providers being taught to engage in informed-consent conversations around prescribing atypical antipsychotics? A lot of my patients are unaware of the metabolic side effects of antipsychotics until they happen. If the residents are going to be advising weight loss after the fact, they should also be discussing it before the fact.- Are providers being taught to screen for current or prior disordered eating before prescribing these medications? Given the likely higher-than-average incidence of eating disorders in psychiatric practice, this seems to be a necessary (though often forgotten) part of counseling patients about weight.2) I wonder what it could look like to have a local family physician or internist (ideally one with a weigh-neutral or weight-inclusive approach) talk to them about what it looks like in practice to prescribe those medications, including duration of treatment, side effect management, discontinuation rates, cost/insurance coverage, prior authorization, etc. I see this as an opportunity for harm reduction.Jess Friedman, MD, MPHBaltimore, Maryland